Article
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.
The Journal of allergy and clinical immunology - 1 Jun 2014
Khattri Saakshi, Shemer Avner, Rozenblit Mariya, Dhingra Nikhil, Czarnowicki Tali, Finney Robert, Gilleaudeau Patricia, Sullivan-Whalen Mary, Zheng Xiuzhong, Xu Hui, Cardinale Irma, de Guzman Strong Cristina, Gonzalez Juana, Suárez-Fariñas Mayte, Krueger Jim G, Guttman-Yassky Emma
Abstract excerpt
BACKGROUND: Atopic dermatitis (AD) is the most common inflammatory disease. Evolving disease models link changes in epidermal growth and differentiation to T(H)2/T(H)22 cytokine activation. However, these models have not been tested by in vivo suppression of T-cell cytokines. Cyclosporine (CsA) is an immunosuppressant that is highly effective for severe disease, but its mechanism in AD skin lesions has not been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.